These results substantiated that NFκB signaling is engaged in KIAA1522 mediated cisplatin resistance, and enlightened us to cooperatively use of NFκB inhibitor and cisplatin to circumvent the treatment-refractory nature of lung adenocarcinomas expressed high level KIAA1522. The gene discussed is NHSL3; the disease is lung adenocarcinoma.